Mohammed Bahey-El-Din

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8836169/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor/herbal therapy of breast cancer. Nanomedicine, 2018, 13, 2637-2656.	3.3	63
2	Enhanced transdermal permeability of Terbinafine through novel nanoemulgel formulation; Development, inÂvitro and inÂvivo characterization. Future Journal of Pharmaceutical Sciences, 2018, 4, 18-28.	2.8	58
3	Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins. Current Gene Therapy, 2010, 10, 34-45.	2.0	56
4	Lactococcus lactis-based vaccines from laboratory bench to human use: An overview. Vaccine, 2012, 30, 685-690.	3.8	56
5	Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8+ T cells against Listeria monocytogenes in the murine infection model. Vaccine, 2008, 26, 5304-5314.	3.8	47
6	Novel lecithin-integrated liquid crystalline nanogels for enhanced cutaneous targeting of terconazole: development, in vitro and in vivo studies. International Journal of Nanomedicine, 2016, Volume 11, 5531-5547.	6.7	42
7	Combining hydrophilic chemotherapy and hydrophobic phytotherapy via tumor-targeted albumin–QDs nano-hybrids: covalent coupling and phospholipid complexation approaches. Journal of Nanobiotechnology, 2019, 17, 7.	9.1	36
8	Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging. Nanomedicine, 2018, 13, 1707-1730.	3.3	30
9	Nisin inducible production of listeriolysin O in Lactococcus lactis NZ9000. Microbial Cell Factories, 2008, 7, 24.	4.0	27
10	<p class="p1"> Efficacy of a <i>Lactococcus lactis</i> î" <i>pyrG</i> vaccine delivery platform expressing chromosomally integrated <i>hly</i> from <i>Listeria monocytogenes</i> . Bioengineered Bugs, 2010, 1, 66-74.	1.7	27
11	Recombinant N-terminal outer membrane porin (OprF) of Pseudomonas aeruginosa is a promising vaccine candidate against both P. aeruginosa and some strains of Acinetobacter baumannii. International Journal of Medical Microbiology, 2020, 310, 151415.	3.6	26
12	Expression of two Listeria monocytogenes antigens (P60 and LLO) in Lactococcus lactis and examination for use as live vaccine vectors. Journal of Medical Microbiology, 2010, 59, 904-912.	1.8	23
13	Lactococcus lactis-based vaccines: Current status and future perspectives. Hum Vaccin, 2011, 7, 106-109.	2.4	23
14	Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model. BMC Infectious Diseases, 2015, 15, 147.	2.9	23
15	Immunization with the outer membrane proteins OmpK17 and OmpK36 elicits protection against Klebsiella pneumoniae in the murine infection model. Microbial Pathogenesis, 2018, 119, 12-18.	2.9	22
16	Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection. Experimental Parasitology, 2014, 145, 51-60.	1.2	20
17	A mutant in the Listeria monocytogenes Fur-regulated virulence locus (frvA) induces cellular immunity and confers protection against listeriosis in mice. Journal of Medical Microbiology, 2013, 62, 185-190.	1.8	19
18	Immunization with the ferric iron-binding periplasmic protein HitA provides protection against Pseudomonas aeruginosa in the murine infection model. Microbial Pathogenesis, 2019, 131, 181-185.	2.9	18

#	Article	IF	CITATIONS
19	Vancomycin-functionalized Eudragit-based nanofibers: Tunable drug release and wound healing efficacy. Journal of Drug Delivery Science and Technology, 2020, 58, 101812.	3.0	12
20	Lactococcus lactis: from the dairy industry to antigen and therapeutic protein delivery. Discovery Medicine, 2010, 9, 455-61.	0.5	12
21	Recombinant expression of the alternate reading frame protein (ARFP) of hepatitis C virus genotype 4a (HCV-4a) and detection of ARFP and anti-ARFP antibodies in HCV-infected patients. Archives of Virology, 2015, 160, 1939-1952.	2.1	10
22	<i>Listeria monocytogenes</i> mutants defective in gallbladder replication represent safety-enhanced vaccine delivery platforms. Human Vaccines and Immunotherapeutics, 2016, 12, 2059-2063.	3.3	10
23	Plant DNA barcoding and metabolomics for comprehensive discrimination of German Chamomile from its poisonous adulterants for food safety. Food Control, 2022, 136, 108840.	5.5	8
24	Two-tiered biological containment strategy for <i>Lactococcus lactis</i> -based vaccine or immunotherapy vectors. Human Vaccines and Immunotherapeutics, 2014, 10, 333-337.	3.3	3
25	Mycothiol acetyltransferase (Rv0819) of <i>Mycobacterium tuberculosis</i> is a potential biomarker for direct diagnosis of tuberculosis using patient serum specimens. Letters in Applied Microbiology, 2017, 65, 504-511.	2.2	3
26	Recombinant Ax21 protein is a promising subunit vaccine candidate against Stenotrophomonas maltophilia in a murine infection model. Vaccine, 2021, 39, 4471-4480.	3.8	3
27	Successful detection, expression and purification of the alternatively spliced truncated Sm14 antigen of an Egyptian strain of Schistosoma mansoni. Journal of Helminthology, 2015, 89, 764-768.	1.0	2
28	Immunization with the basic membrane protein (BMP) family ABC transporter elicits protection against Enterococcus faecium in a murine infection model. Microbes and Infection, 2020, 22, 127-136.	1.9	2
29	Bacterial Ghosts of Pseudomonas aeruginosa as a Promising Candidate Vaccine and Its Application in Diabetic Rats. Vaccines, 2022, 10, 910.	4.4	2
30	Vaccination Studies: Detection of a Listeria monocytogenes-Specific T Cell Immune Response Using the ELISPOT Technique. Methods in Molecular Biology, 2014, 1157, 263-274.	0.9	1